Vertex (VRTX) PT Raised to $220 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/9/2026
- S&P 500, Nasdaq fall as tech selling resumes, Trump vows to respond to downed US helicopter
- Oil prices fall to seven-week low as Iran and Israel halt attacks
- Micron to deliver 'another strong quarter', Goldman says
- Potential implications from SpaceX IPO for Tesla?
- TSMC falls as Taiwan mulls curbs on AI chip exports to China
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Micron to deliver 'another strong quarter', Goldman says
- UK's Ofcom requires tech firms to create crisis response plans
- Supermicro plans $7 billion financing to fund AI server orders
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
Vertex Reports Full-Year and Fourth-Quarter 2018 Financial Results
February 5, 2019 4:01 PM EST- Full-year 2018 CF product revenues of $3.04 billion, a 40% increase compared to $2.17 billion in 2017; fourth-quarter 2018 CF product revenues of $868 million -
- Full-year 2018 GAAP operating income increased 415% to $635 million; non-GAAP operating income increased 97% to $1.11 billion -
- Company provides full-year 2019 financial guidance for total CF product revenues of $3.45 billion to $3.55 billion -
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full year and fourth quarter ended December 31, 2018 and provided full-year 2019 financial guidance.
Fourth-Quarter and Full-Year 2018 Financial Highlights
Three Months Ended
December 31,
